Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; A… Read more
Autolus Therapeutics plc (6A3A) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.256x
Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.256x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-67.90 Million) by net assets (€265.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Autolus Therapeutics plc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
-0.011x |
|
Vuzix Corp.
LSE:0LRL
|
-0.132x |
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.038x |
|
MAKUS Inc
KQ:093520
|
0.021x |
|
Gamania Digital Entertainment Co Ltd
TWO:6180
|
0.232x |
|
Melar Acquisition Corp. I Class A Ordinary Shares
NASDAQ:MACI
|
-0.001x |
|
VOXEL SA ZY 1
F:0NX
|
N/A |
|
Ege Gubre Sanayi AS
IS:EGGUB
|
0.147x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €427.32 Million | €-206.27 Million | -0.483x | +63.04% |
| 2023-12-31 | €111.47 Million | €-145.59 Million | -1.306x | -247.32% |
| 2022-12-31 | €298.67 Million | €-112.31 Million | -0.376x | +0.04% |
| 2021-12-31 | €313.32 Million | €-117.86 Million | -0.376x | +32.91% |
| 2020-12-31 | €210.03 Million | €-117.76 Million | -0.561x | -40.79% |
| 2019-12-31 | €254.84 Million | €-101.48 Million | -0.398x | -139.23% |
| 2018-12-31 | €255.47 Million | €-42.52 Million | -0.166x | -45.09% |
| 2017-12-31 | €142.60 Million | €-16.36 Million | -0.115x | -- |